A carregar...
Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies
Glasdegib is approved for treating acute myeloid leukemia in elderly patients at 100 mg once daily in combination with low‐dose cytarabine. Exposure‐efficacy analysis showed that the survival benefit of glasdegib was not glasdegib exposure‐dependent. The relationship between glasdegib exposure and a...
Na minha lista:
| Publicado no: | J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7891441/ https://ncbi.nlm.nih.gov/pubmed/32974950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1742 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|